Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Puma Biotechnology (PBYI) over the last 5 years, with Sep 2025 value amounting to $26,000.

  • Puma Biotechnology's Capital Expenditures rose 30.00% to $26,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $123,000, marking a year-over-year increase of 9.82%. This contributed to the annual value of $56,000 for FY2024, which is 60.00% down from last year.
  • As of Q3 2025, Puma Biotechnology's Capital Expenditures stood at $26,000, which was up 30.00% from $20,000 recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Capital Expenditures peaked at $7.0 million during Q3 2022, and registered a low of -$7.0 million during Q4 2022.
  • Over the past 3 years, Puma Biotechnology's median Capital Expenditures value was $23,000 (recorded in 2024), while the average stood at $29,375.
  • Over the last 5 years, Puma Biotechnology's Capital Expenditures had its largest YoY gain of 100.64% in 2023, and its largest YoY loss of 99.61% in 2023.
  • Puma Biotechnology's Capital Expenditures (Quarterly) stood at -$7.0 million in 2022, then skyrocketed by 100.64% to $45,000 in 2023, then crashed by 64.44% to $16,000 in 2024, then soared by 30.00% to $26,000 in 2025.
  • Its Capital Expenditures stands at $26,000 for Q3 2025, versus $20,000 for Q2 2025 and $61,000 for Q1 2025.